Trial site
Taian City Central Hospital
- 13running trials
- 6closed trials
The trials here
What the 19 trials at this site are about, from their registry records.
- Conditions
- Ulcerative colitis6 trials
- Chronic lymphocytic leukaemia2 trials
- Irritable bowel syndrome2 trials
- Atrial fibrillation1 trial
- Bladder cancer1 trial
- Chronic kidney disease1 trial
- Colorectal cancer1 trial
- Gastric and oesophageal cancer1 trial
- IgA nephropathy1 trial
- Metastatic breast cancer1 trial
- Myelodysplastic syndromes1 trial
- Stroke1 trial
- Phase
- Phase 311 trials
- Phase 27 trials
- Status
- Recruiting6 trials
- Active, not recruiting5 trials
- Completed4 trials
- Not yet recruiting2 trials
- Terminated1 trial
- Withdrawn1 trial
- Lead sponsor
- Eli Lilly and Company8 trials
- BeOne Medicines2 trials
- Janssen Research & Development, LLC2 trials
- Qilu Hospital of Shandong University2 trials
- Alpine Immune Sciences Inc, A Subsidiary of Vertex1 trial
- and 4 more
Running trials
Recruiting
A Study of Brenipatide (LY3537031) in Participants With Irritable Bowel Syndrome-Diarrhea (IBS-D)
Recruiting
Recruiting
LY4268989 in Adults With Moderately to Severely Active Ulcerative Colitis
Recruiting
Active, not recruiting
Recruiting
Active, not recruiting
Recruiting
Recruiting
First-line Treatment With RC48 Plus Sintilimab and S-1 in Advanced Gastric Cancer (RCTS2)
Recruiting
Active, not recruiting
Evaluation of Efficacy of Povetacicept in Adults With Immunoglobulin A Nephropathy (IgAN)
Active, not recruiting
A Study of Milvexian Versus Apixaban in Participants With Atrial Fibrillation
Active, not recruiting
Recruiting at the same time
How many trials recruit for the same indication here at once. A count, not a rating.
- Irritable bowel syndrome2 recruiting
- Ulcerative colitis2 recruiting
- Bladder cancer1 recruiting
- Chronic lymphocytic leukaemia1 recruiting
- Colorectal cancer1 recruiting
- Gastric and oesophageal cancer1 recruiting
Closed trials
Withdrawn
Efficacy and Safety of Volenrelaxin in Adults With Chronic Kidney Disease
Terminated
Completed
Completed
GB491 Combined With Fulvestrant for HR+ HER2- Locally Advanced or Metastatic Breast Cancer
Completed
Completed
Site data: ClinicalTrials.govUpdated 14 Nov 2026